WEGOVY (semaglutide) prescribing information (Label 215256s024)
Critical Appraisal Internal Validity Withdrawals from study were less than 10% in all groups across all studies, and in many groups were less than 5%, with no clear and consistent differences in study withdrawals between groups
As may be expected, mean diabetes duration tended to be longer in patients receiving a greater number of background medications, ranging from 7.2 to 10.6 years in patients on metformin monotherapy to 8.4 to 17.3 years in patients receiving more than one background medication
It's totally valid to wonder what happens next if you have significant side effects while taking semaglutide for weight loss
The FDA has issued public warnings about dosing errors and adverse events involving compounded semaglutide and tirzepatide - with more than 1,700 adverse events linked to compounded semaglutide and tirzepatide combined as of May 21, 2026, according to FDA's published adverse event data